Since its establishment in 2013, Promed has been driven by research and innovation, committed to delivering precise and accessible high-end diagnostic solutions.
We independently developed the world’s first Microfluidic Thromboelastography System, ST-1000, enabling accurate bedside testing with performance on par with international standards. At the same time, we have been deeply focusing on our Fluorescence Immunoassay Platform, targeting key maternal and child health markers such as Vitamin D and Ferritin, complemented by inflammation and cardiac markers, providing fully quantitative, reliable data to support precise clinical decision-making.
Guided by our mission — “Diagnostics for All, Safeguarding Global Health” — Promed continues to innovate, delivering advanced and reliable diagnostic technologies to patients around the world.
The immunofluorescence platform includes 50+ kinds of reagents and three high-performance devices, focusing on detecting cardiovascular disease, inflammation, kidney injury, sex hormones, thyroid function, diabetes, tumor, and others.
The colloidal gold platform can cover the detection of more than 20 kinds of markers, such as clinical common inflammation and infection, stomach health, cardiovascular and cerebrovascular, bone health, iron deficiency anemia, pregnancy detection, renal function detection, etc.
Diagnosis of coagulation and fibrinolysis
Since its establishment, our factory has been developing first world class products with adhering the principle of quality first. Our products have gained excellent reputation in the industry and valuabletrusty among new and old customers..
submit now